MEZIS e.V.Das renommierte BMJ berichtet über Interessenkonflikte der amerikanischen FDA-Gutachter, die ein neues, umstrittenes Alzheimer-Medikament zugelassen haben ... und bei der Firma Lilly auf der Gehaltsliste standen:
https://www.bmj.com/content/386/bmj.q2010
Kann bei uns in Deutschland nicht passieren?
Nun ... Lilly hat nicht nur in den deutschen Leitlinien gewogene Autoren positioniert (siehe www.leitlinienwatch.de) sondern exquisiten Zugang zur Regierung:
"Im April war Spatenstich für das neue Lilly-Werk in Alzey und da sagte Bundeskanzler Scholz wörtlich: „Was immer wir als Bund tun können, um den Pharmastandort Deutschland noch weiter zu stärken, das werden wir tun. Ich erinnere mich an unser Telefonat, lieber Dave Ricks (Geschäftsführer von Eli Lilly, Anm. d. Redaktion), und daran, wie viele Gespräche Sie auch mit dem Wirtschafts- und dem Gesundheitsminister und mit der Wissenschaftsministerin geführt haben, um die Weichen für diese Investition zu stellen.“ Zitat TAZ (https://taz.de/!6018297/).
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory panellists who recommended approval. Jeanne Lenzer and Shannon Brownlee report Donanemab (marketed in the US as Kisunla) was developed by Eli Lilly and approved by the US Food and Drug Administration (FDA) on 2 July. It is the latest in a new class of treatments for Alzheimer’s disease that has been much praised in the media as “breakthrough drugs” and the first “disease modifying therapies” for the condition. All drugs in the class deliver antibodies that target β amyloid, a protein believed to cause the disease, and they share similar benefits and harms. Their effectiveness, however, has been questioned. George Perry, editor in chief of the Journal of Alzheimer’s Disease, told The BMJ that the new anti-amyloid drugs, such as aducanumab and lecanemab, “all demonstrate an imperceptible slowing of dementia in the midst of serious adverse effects, including death.” Donanemab, like the two previously approved Alzheimer’s drugs, faces questions not only about its efficacy and the number of deaths among patients taking the drug but also about financial ties to drug makers among FDA advisory committee members. The BMJ has found that three advisers who recommended approval of donanemab received direct payments or research funding from its manufacturer, Lilly. In January 2023 the FDA sent a letter to Lilly denying approval of donanemab.1 In a briefing document the agency cited a “high rate” of missing data and concluded that the “safety database was insufficient to adequately characterize the long-term safety” of the drug.2 The FDA noted that treatment discontinuation because of adverse events was more common among patients taking donanemab than in the placebo group in Lilly’s phase 3 trial. Patients who …
शून्यता
Alastair Bor 🇦🇺
Cuz 
